Subjects with hypersensitivity to sumatriptan

Subjects with history, symptoms, or signs of myocardial infarction, ischemic cardiac disease, or variant angina

Subjects with history of peripheral vascular disorder

Subjects with history of cerebrovascular disorder or transient ischemic attacks

Subjects with uncontrolled high-blood pressure

Subjects with severe hepatic function disorder

Subjects taking ergotamine, ergotamine derivative containing product, or 5-HT1B/1D agonist

Subjects taking monoamine oxidaze inhibitor or use within 2 weeks of discontinuation

Drug Use Investigation for IMIGRAN Tablet